Pacira BioSciences (PCRX) Non-Current Debt (2010 - 2026)

Pacira BioSciences' Non-Current Debt history runs 10 years deep, the most recent figure standing at $367.7 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 262.26% year-over-year to $367.7 million in Q1 2026; TTM through Mar 2026 was $367.7 million, a 262.26% increase from a year earlier, with the FY2025 full-year figure at $372.2 million, down 36.41% from the prior year.
• Non-Current Debt slipped to $367.7 million in Q1 2026 per PCRX's latest filing, from $372.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $689.5 million in Q4 2022 and bottomed at $97.8 million in Q2 2025.
• The 5-year median for Non-Current Debt is $309.8 million (2022), against an average of $281.6 million.
• Across the five-year window, Non-Current Debt sank 61.93% in 2023 and jumped 262.26% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $689.5 million in 2022, then fell by 24.23% to $522.4 million in 2023, then increased by 12.04% to $585.3 million in 2024, then tumbled by 36.41% to $372.2 million in 2025, then declined by 1.22% to $367.7 million in 2026.
• Per Business Quant, the three latest PCRX Non-Current Debt figures stand at $367.7 million (Q1 2026), $372.2 million (Q4 2025), and $376.7 million (Q3 2025).